amitriptyline has been researched along with Vascular Diseases in 5 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The gene for sickle cell disease is carried by 8% of the African-American population in the United States." | 1.28 | Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. ( Pollack, CV; Sanders, DY; Severance, HW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Emery, CJ | 1 |
| Laude, E | 1 |
| Herget, J | 1 |
| Gill, G | 1 |
| Cope, G | 1 |
| Barer, GR | 1 |
| Sanders, DY | 1 |
| Severance, HW | 1 |
| Pollack, CV | 1 |
| Brechter, CL | 1 |
| Gisslén, H | 1 |
| Mobacken, H | 1 |
| Haefely, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis[NCT00094887] | Phase 2 | 150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospitalization is defined as the length of time from admission to discharge order (NCT00094887)
Timeframe: within 40 days
| Intervention | Days (Median) |
|---|---|
| Inhaled Nitric Oxide | 4.06 |
| Placebo | 3.11 |
(NCT00094887)
Timeframe: within 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 5 |
| Placebo | 7 |
Number of participants who required a blood transfusion before discharge because of acute chest syndrome/pneumonia (NCT00094887)
Timeframe: within 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 8 |
| Placebo | 7 |
"VOC resolution was defined by all of the following conditions:~Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best)~Freedom from parenteral narcotic use,~Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis,~Subject and/or family's belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment." (NCT00094887)
Timeframe: within 30 days
| Intervention | Hours (Median) |
|---|---|
| Inhaled Nitric Oxide | 61.83 |
| Placebo | 55.16 |
The number of participants readmitted to the hospital for any reason within 30 days after discharge (NCT00094887)
Timeframe: during first 24 hours and during 30 day follow-up
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| during first 24 hours | during 30-day follow-up | |
| Inhaled Nitric Oxide | 0 | 9 |
| Placebo | 0 | 17 |
The total dose (mg) of opioid medications received during the trial (NCT00094887)
Timeframe: within 8 hours and within 40 days
| Intervention | mg (Median) | |
|---|---|---|
| within 8 hours | within 40 days | |
| Inhaled Nitric Oxide | 16.25 | 153.75 |
| Placebo | 17.25 | 211.37 |
1 review available for amitriptyline and Vascular Diseases
| Article | Year |
|---|---|
[Drugs with effect on the adrenergic nerve fiber].
Topics: Aminocaproates; Amitriptyline; Amphetamine; Bretylium Compounds; Chlorpromazine; Disulfiram; Dopamin | 1968 |
4 other studies available for amitriptyline and Vascular Diseases
| Article | Year |
|---|---|
Adverse pulmonary vascular effects of high dose tricyclic antidepressants: acute and chronic animal studies.
Topics: Acute Disease; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Cats; Chronic Disease; Dise | 2002 |
Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department.
Topics: Acetaminophen; Adolescent; Adult; Amitriptyline; Analgesics; Anemia, Sickle Cell; Anti-Inflammatory | 1992 |
Another amitriptyline side-effect?
Topics: Amitriptyline; Humans; Male; Middle Aged; Paresis; Vascular Diseases | 1968 |
[Vasculitis in amitriptyline therapy].
Topics: Amitriptyline; Drug Eruptions; Drug Tolerance; Female; Hematuria; Humans; Kidney; Male; Middle Aged; | 1969 |